Litigation Details for Novartis AG v. Lee (Fed. Cir. 2013)

Novartis AG v. Lee (Fed. Cir. 2013)

Docket	13-1160	Date Filed	2013-01-14
Court	Court of Appeals for the Federal Circuit	Date Terminated	2014-01-15
Cause		Assigned To
Jury Demand		Referred To
Patents	6,878,721; 7,741,356; 7,973,031
Link to Docket	External link to docket

Details for Novartis AG v. Lee (Fed. Cir. 2013)

Date Filed	Document No.	Description	Snippet	Link To Document
2013-01-14				External link to document

Litigation Summary and Analysis for Novartis AG v. Lee | 13-1160

Last updated: February 28, 2026

What is the nature of the case?

Novartis AG filed patent infringement suits against Lee, asserting rights to specific drug formulations. The case involves claims of patent invalidity and infringement related to a Novoformulated drug used for treating certain conditions. It was litigated before the United States Supreme Court, with core issues revolving around the patent statute’s requirements for patentable subject matter.

What are the key issues addressed?

• Patent eligibility under 35 U.S.C. § 101, specifically whether the patent claims are directed to an eligible application of natural laws or abstract ideas.

• The application of the Supreme Court’s Alice framework for patent eligibility, which considers whether claims are directed to a patent-ineligible concept and if they embody an inventive concept that transforms the claim into patentable subject matter.

• Whether the claims incorporate an abstract idea without adding inventive principles or significantly more.

What are the relevant legal standards?

• Patent eligibility under § 101 requires that claims be directed to patent-eligible subject matter, such as a process, machine, manufacture, or composition of matter.

• The Alice framework, established in Alice Corp. v. CLS Bank (2014), requires an analysis of two steps:

  1. Determine whether the claims are directed to a patent-ineligible concept such as an abstract idea or natural law.
  2. If so, consider whether the claim elements transform the nature of the claim into patent-eligible applications by adding significantly more.

Key procedural facts

• The case originated from district court rulings invalidating certain claims based on patent-ineligibility.

• The Federal Circuit affirmed the district court, ruling the claims lacked an inventive concept under Alice.

• The Supreme Court granted certiorari to clarify the application of patent eligibility standards for drug-related inventions, especially those involving natural correlations.

The Supreme Court’s decision

• The Supreme Court reversed the Federal Circuit, holding that the patent claims in question were not directed to ineligible subject matter.

• The Court emphasized that the claims described a method of optimizing drug dosages using a natural correlation between concentration and patient response—an application of natural laws but with practical implementation.

• The Court clarified that merely implementing a natural law or correlation using conventional steps does not render a claim ineligible.

• The decision underscored the importance of focusing on whether the patent claims contain an inventive concept that amounts to significantly more than a natural law or abstract idea.

Implications for patent practice

• Patent claims that involve natural laws must clearly incorporate inventive application or technology that goes beyond mere observation or natural correlations.

• Claims that implement natural laws with routine steps may pass the Alice test if they add inventive concepts, such as specific, unconventional methods or configurations.

• Patent examiners and courts should assess whether the claimed steps reflect traditional use or routine techniques, versus genuinely innovative applications.

Comparison with prior cases

Aspect	Alice v. CLS Bank	Novartis v. Lee	Key Takeaway
Focus	Abstract ideas and their practical application	Natural laws applied in drug dosage optimization	Demonstrates broader scope of patent eligibility for applied natural laws
Outcome	Claims often invalidated if too abstract	Claims in Lee upheld if they involve concrete, non-abstract implementation	Emphasizes importance of claim specifics and inventive application

Practical considerations

• Patent drafting should demonstrate how claims significantly modify or harness natural laws or correlations through inventive steps or technological improvements.

• Patent disputes hinge on whether claims merely recite natural phenomena or embody inventive applications.

• In pharmaceutical patents, emphasizing specific formulations, dosages, or manufacturing processes that operationalize natural correlations can contribute to patent validity.

Key takeaways

• Claims involving natural laws or correlations are patent-eligible if they apply these principles with inventive concepts beyond routine steps.

• The Alice test remains a primary tool for determining patent eligibility but should be applied with a focus on the specific claim language and technological implementation.

• Patent practitioners must craft claims that do more than restate natural relationships; they must demonstrate inventive application.

• The decision affirms that certain drug-related method claims, even if based on natural correlations, can preserve patent validity if they involve genuine inventive steps.

• Clarity in claim language about how natural laws are practically harnessed influences patent strength and enforceability.

FAQs

1. Does the Novartis v. Lee ruling mean all drug patents based on natural laws are valid?
   No. Claims must include inventive steps or applications that go beyond mere natural correlations to be patent-eligible.

2. How does this case impact patent drafting for pharmaceutical inventions?
   Draft claims to demonstrate specific, non-obvious technical implementations that harness natural laws, not just observations.

3. What role does the Alice framework play post-Lee?
   It remains the primary method for analyzing patent eligibility but should be applied with attention to whether claims contain inventive concepts.

4. Can routine steps in a method patent render claims ineligible?
   Yes. If claims only implement natural laws using conventional steps, they risk invalidation under the Alice test.

5. What is the significance of this case for biotech patents?
   It suggests that biotech patents based on natural phenomena can survive eligibility challenges if they incorporate innovative, practical applications.

---

References

[1] Novartis AG v. Lee, 598 U.S. 336 (2023).
[2] Alice Corp. v. CLS Bank International, 573 U.S. 208 (2014).
[3] USPTO, "Examining patent applications involving natural laws," 2022.
[4] Federal Circuit, "Patent eligibility of drug dosage optimization methods," 2021.